{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Heavican-Foral TB"],"funding":["NCI NIH HHS"],"pagination":["2452-2464"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12463675"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(10)"],"pubmed_abstract":["Chimeric antigen receptor (CAR) T cell therapy has not yet been realized for T-cell lymphomas (TCL), partially due to challenges in identifying tumor-specific antigens. We previously reported selective expression of CD37 on malignant T cells in a subset of TCL. Herein, we demonstrate CAR-37 T cells specifically target CD37-positive TCL in part by activating the intrinsic apoptotic pathway. To maximize therapeutic index, we identified selective/targetable BH3 dependences in individual TCL models and combined with CAR-37 T cells. We show that BH3 mimetics do not alter CD37 antigen binding capacity on TCL and have minimal effects on CAR-37 T-cell phenotype or function. In TCL models with dependence on MCL-1, combining CAR-37 T cells and the MCL-1 inhibitor AZD5991 increases anti-TCL response "],"journal":["Leukemia"],"pubmed_title":["Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma."],"pmcid":["PMC12463675"],"funding_grant_id":["R01 CA249185","R01 CA249062","R35 CA231958","R35 CA210030","P01 CA233412"],"pubmed_authors":["Stegmaier K","Lohr JG","Liu J","Letai A","Wiggers CRM","Korell F","Wu G","Hegel J","Weinstock DM","B AT","Eisenbies Z","Silva H","Powers F","Scarfo I","Heavican-Foral TB","Knoechel B","Maus MV","Kulp S"],"additional_accession":[]},"is_claimable":false,"name":"Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.","description":"Chimeric antigen receptor (CAR) T cell therapy has not yet been realized for T-cell lymphomas (TCL), partially due to challenges in identifying tumor-specific antigens. We previously reported selective expression of CD37 on malignant T cells in a subset of TCL. Herein, we demonstrate CAR-37 T cells specifically target CD37-positive TCL in part by activating the intrinsic apoptotic pathway. To maximize therapeutic index, we identified selective/targetable BH3 dependences in individual TCL models and combined with CAR-37 T cells. We show that BH3 mimetics do not alter CD37 antigen binding capacity on TCL and have minimal effects on CAR-37 T-cell phenotype or function. In TCL models with dependence on MCL-1, combining CAR-37 T cells and the MCL-1 inhibitor AZD5991 increases anti-TCL response ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-07-15T06:51:46.935Z","creation":"2026-06-30T03:28:12.907Z"},"accession":"S-EPMC12463675","cross_references":{"pubmed":["40739330"],"doi":["10.1038/s41375-025-02697-1"]}}